Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1

Status

Recruiting 3Not yet recruiting 2Approved for marketing 1Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Observational 3Interventional 3Expanded_access 1

Sponsor

Cancer Type

CNS 7

Conditions

Glioma 7Astrocytoma 4Oligodendroglioma 2Brain Neoplasms 2Recurrence 1Pathologic Processes 1Neuroectodermal Tumors 1Neoplasms, Neuroepithelial 1Neoplasms, Nerve Tissue 1Neoplasms, Glandular and Epithelial 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Histologic Type 1Neoplasms 1Lymphoma, Follicular 1Healthy Adult Participants 1Disease Attributes 1

Interventions

Temozolomide 159Bevacizumab 69Radiotherapy 68Magnetic Resonance Spectroscopy 68Irinotecan 31Surgical Procedures, Operative 27Radiation 24Carboplatin 23Specimen Handling 20Carmustine 20Blood Specimen Collection 20Nivolumab 19Aminolevulinic Acid 18Biopsy 17Lomustine 16pembrolizumab 13Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13trametinib 12fluorodopa F 18 12X-Rays 12Radiosurgery 12Erlotinib Hydrochloride 12Topotecan 11Everolimus 11Magnetic Resonance Imaging 10IL13-PE38 10dabrafenib 9Etoposide 9Drug Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Glioma × vorasidenib × Clear all
NCT07629089 2026-06-05

VALIENT

University of Pittsburgh

Phase 1 Not yet recruiting
24 enrolled
CNS

Brain Neoplasms, Glioma

NCT07547163 2026-04-23

LGG PRO's

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

Recruiting
90 enrolled
CNS

Glioma

NCT07240662 2026-01-09

VIOLETA

iOMEDICO AG

Recruiting
150 enrolled
CNS

Glioma

NCT05609994 2025-07-18

ViCToRy

Duke University

Phase 1 Recruiting
48 enrolled
CNS

Brain Neoplasms, Glioma

NCT06969352 2025-05-13

VICTORIA

Servier (Tianjin) Pharmaceutical Co. LTD.

Not yet recruiting
60 enrolled
CNS

Glioma

NCT04164901 2025-04-03

Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

Servier

Phase 3 Active not recruiting
331 enrolled 25 charts 1 FDA
CNS

Glioma

NCT05592743 2024-11-05

Vorasidenib Expanded Access Program

Servier

Approved for marketing
CNS

Astrocytoma, Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Oligodendroglioma, Pathologic Processes, Recurrence, Neuroectodermal Tumors, Neoplasms, Neuroepithelial, Disease Attributes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡